| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Carcinogenesis |
Department of Pharmacology, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030 [D. J. L., A. G., A. K. J.]; Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 [A. M., S. P.]; Lexicon Genetics, Woodlands, Texas 77381 [C. A. M.]; and National Cancer Institute, Bethesda, Maryland 20892 [F. J. G.]
NAD(P)H:quinone oxidoreductase1 (NQO1) is a cytosolic protein that reduces and detoxifies quinones and their derivatives, thus protecting cells against redox cycling and oxidative stress. Disruption of the NQO1 gene in mice caused myeloid hyperplasia of bone marrow and highly significant increases in blood neutrophils, eosinophils, and basophils. NQO1-null mice also showed a decrease in lymphocytes and WBCs as compared with wild-type mice. Various techniques also demonstrated an increase in megakaryocytes without an increase in blood platelets. Histological analysis of liver, kidney, spleen, and thymus did not demonstrate a difference between wild-type and NQO1-null mice or a sign of infection. Blood cultures and urine analysis also did not demonstrate any sign of infection in NQO1-null and wild-type mice. Additional analysis of the bone marrow from NQO1-null mice revealed that loss of NQO1 alters the intracellular redox status because of accumulation of NAD(P)H, cofactors for NQO1. This causes a reduction in the levels of pyridine nucleotides and tumor suppressor proteins p53 and p73, and a decrease in apoptosis. The decrease in apoptosis causes myelogenous hyperplasia in NQO1-null mice. These results demonstrate that NQO1 acts as an endogenous factor in the protection against myelogenous hyperplasia. This is significant because 2–4% of human individuals without known abnormalities, and >25% of individuals with benzene poisoning and acute myelogenic leukemia are homozygous for a mutant allele (P187S) of NQO1 and lack NQO1 protein/activity.
This article has been cited by other articles:
|
|
 |
|
  L.-H. Ding, Y. Xie, S. Park, G. Xiao, and M. D. Story Enhanced identification and biological validation of differential gene expression via Illumina whole-genome expression arrays through the use of the model-based background correction methodology Nucleic Acids Res., June 1, 2008; 36(10): e58 - e58. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Gong, L. Kole, K. Iskander, and A. K. Jaiswal NRH:Quinone Oxidoreductase 2 and NAD(P)H:Quinone Oxidoreductase 1 Protect Tumor Suppressor p53 against 20S Proteasomal Degradation Leading to Stabilization and Activation of p53 Cancer Res., June 1, 2007; 67(11): 5380 - 5388. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Begleiter, D. Hewitt, A. W. Maksymiuk, D. A. Ross, and R. P. Bird A NAD(P)H:Quinone Oxidoreductase 1 Polymorphism Is a Risk Factor for Human Colon Cancer Cancer Epidemiol. Biomarkers Prev., December 1, 2006; 15(12): 2422 - 2426. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Iskander, J. Li, S. Han, B. Zheng, and A. K. Jaiswal NQO1 and NQO2 Regulation of Humoral Immunity and Autoimmunity J. Biol. Chem., October 13, 2006; 281(41): 30917 - 30924. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kannan and A. K. Jaiswal Low and High Dose UVB Regulation of Transcription Factor NF-E2-Related Factor 2. Cancer Res., September 1, 2006; 66(17): 8421 - 8429. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. S. Ahn, G. Sethi, A. K. Jain, A. K. Jaiswal, and B. B. Aggarwal Genetic Deletion of NAD(P)H:Quinone Oxidoreductase 1 Abrogates Activation of Nuclear Factor-{kappa}B, I{kappa}B{alpha} Kinase, c-Jun N-terminal Kinase, Akt, p38, and p44/42 Mitogen-activated Protein Kinases and Potentiates Apoptosis J. Biol. Chem., July 21, 2006; 281(29): 19798 - 19808. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Merker, S. H. Audi, R. D. Bongard, B. J. Lindemer, and G. S. Krenz Influence of pulmonary arterial endothelial cells on quinone redox status: effect of hyperoxia-induced NAD(P)H:quinone oxidoreductase 1 Am J Physiol Lung Cell Mol Physiol, March 1, 2006; 290(3): L607 - L619. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Karawajew, P. Rhein, G. Czerwony, and W.-D. Ludwig Stress-induced activation of the p53 tumor suppressor in leukemia cells and normal lymphocytes requires mitochondrial activity and reactive oxygen species Blood, June 15, 2005; 105(12): 4767 - 4775. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Iskander, A. Gaikwad, M. Paquet, D. J. Long II, C. Brayton, R. Barrios, and A. K. Jaiswal Lower Induction of p53 and Decreased Apoptosis in NQO1-Null Mice Lead to Increased Sensitivity to Chemical-Induced Skin Carcinogenesis Cancer Res., March 15, 2005; 65(6): 2054 - 2058. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Asher, P. Tsvetkov, C. Kahana, and Y. Shaul A mechanism of ubiquitin-independent proteasomal degradation of the tumor suppressors p53 and p73 Genes & Dev., February 1, 2005; 19(3): 316 - 321. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Sankaranarayanan and A. K. Jaiswal Nrf3 Negatively Regulates Antioxidant-response Element-mediated Expression and Antioxidant Induction of NAD(P)H:Quinone Oxidoreductase1 Gene J. Biol. Chem., December 3, 2004; 279(49): 50810 - 50817. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Iskander, M. Paquet, C. Brayton, and A. K. Jaiswal Deficiency of NRH:Quinone Oxidoreductase 2 Increases Susceptibility to 7,12-Dimethylbenz(a)anthracene and Benzo(a)pyrene-Induced Skin Carcinogenesis Cancer Res., September 1, 2004; 64(17): 5925 - 5928. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Bloom and A. K. Jaiswal Phosphorylation of Nrf2 at Ser40 by Protein Kinase C in Response to Antioxidants Leads to the Release of Nrf2 from INrf2, but Is Not Required for Nrf2 Stabilization/Accumulation in the Nucleus and Transcriptional Activation of Antioxidant Response Element-mediated NAD(P)H:Quinone Oxidoreductase-1 Gene Expression J. Biol. Chem., November 7, 2003; 278(45): 44675 - 44682. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Henderson and C. R. Wolf Transgenic Analysis of Human Drug-Metabolizing Enzymes: Preclinical Drug Development and Toxicology Mol. Interv., September 1, 2003; 3(6): 331 - 343. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Begleiter, K. Sivananthan, T. J. Curphey, and R. P. Bird Induction of NAD(P)H Quinone: Oxidoreductase1 Inhibits Carcinogen-induced Aberrant Crypt Foci in Colons of Sprague-Dawley Rats Cancer Epidemiol. Biomarkers Prev., June 1, 2003; 12(6): 566 - 572. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Anwar, D. Dehn, D. Siegel, J. K. Kepa, L. J. Tang, J. A. Pietenpol, and D. Ross Interaction of Human NAD(P)H:Quinone Oxidoreductase 1 (NQO1) with the Tumor Suppressor Protein p53 in Cells and Cell-free Systems J. Biol. Chem., March 14, 2003; 278(12): 10368 - 10373. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Bauer, B. Faiola, D. J. Abernethy, R. Marchan, L. J. Pluta, V. A. Wong, K. Roberts, A. K. Jaiswal, F. J. Gonzalez, B. E. Butterworth, et al. Genetic Susceptibility to Benzene-induced Toxicity: Role of NADPH: Quinone Oxidoreductase-1 Cancer Res., March 1, 2003; 63(5): 929 - 935. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Long II, K. Iskander, A. Gaikwad, M. Arin, D. R. Roop, R. Knox, R. Barrios, and A. K. Jaiswal Disruption of Dihydronicotinamide Riboside:Quinone Oxidoreductase 2 (NQO2) Leads to Myeloid Hyperplasia of Bone Marrow and Decreased Sensitivity to Menadione Toxicity J. Biol. Chem., November 22, 2002; 277(48): 46131 - 46139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Asher, J. Lotem, L. Sachs, C. Kahana, and Y. Shaul Mdm-2 and ubiquitin-independent p53 proteasomal degradation regulated by NQO1 PNAS, October 1, 2002; 99(20): 13125 - 13130. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
